Ultevursen
- Generic Name
- Ultevursen
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2642382-41-8
- Unique Ingredient Identifier
- 94AC8YWE3I
- Background
Ultevursen is a single-stranded RNA-based oligonucleotide targeting exon 13 of the USH2A gene that encodes usherin. It was developed by ProQR Therapeutics and is being investigated for the treatment of retinitis pigmentosa.
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)
- First Posted Date
- 2021-12-15
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 7
- Registration Number
- NCT05158296
- Locations
- 🇺🇸
Emory Eye Center, Atlanta, Georgia, United States
🇺🇸Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸Center for Clinical Research Operations, Massachusetts Eye and Ear, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath